Research programme: asparaginase-based therapeutics - Jazz Pharmaceuticals

Drug Profile

Research programme: asparaginase-based therapeutics - Jazz Pharmaceuticals

Alternative Names: PASylated asparaginase; Recombinant crisantaspase - Jazz Pharmaceuticals

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jazz Pharmaceuticals Inc
  • Class Amidohydrolases; Antineoplastics; Enzymes
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Haematological disorders

Most Recent Events

  • 26 Jul 2017 Preclinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
  • 26 Jul 2017 Jazz Pharmaceuticals in-licenses PASylation® Technology from XL-protein
  • 26 Jun 2017 Preclinical trials in Haematological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top